Insights

article

The right choice of organic reagents early in the synthesis can smooth the path and expediate the journey of lead- to- candidate identification. Curia can produce the green and versatile reagent T3P in a superior purity – and give researchers the f...

infographic

We offer a robust portfolio of market-leading APIs and world-class capabilities in niche and high-barrier-to-entry technologies.

article

CDMOs that routinely handle highly potent compounds must raise the bar for containment, safety, and industrial hygiene. Diverse capabilities across chemistries, purification technologies, and analytical techniques — combined with the ability to sup...

article

Xtalks spoke with Dr. Steef Boerrigter, a senior research scientist at Curia and an expert at materials science. He has extensive experience with experimental screening technologies for polymorphs, salts and cocrystals and has developed computationa...

webinar

Curia offers more than 240 high-quality, competitively priced APIs and intermediates, including generics, that cover a variety of therapeutic areas. Take a look at our recently filed DMFs.

webinar

Oftentimes, the HPAPI sphere places the spotlight on manufacturing due to the containment challenges on large scale however; handling and containment strategies are also relevant in manufacture support roles such as chemical development, analytical...

article

A panel of experts share their views on some of the critical issues facing the pharmaceutical industry in regards to API sourcing, new API technical services or manufacturing technologies, guidance on choosing a supplier for API research/development...

webinar

Are you looking for the right contract development and manufacturing organization (CDMO) to develop and manufacture your high potency active pharmaceutical ingredients (HPAPIs)? Or have you been unsure about the CDMO you’re currently working with...